Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial.

Horton, S, Jones, AP, Guly, CM, Hardwick, B, Beresford, MW ORCID: 0000-0002-5400-9911, Lee, RWJ, Dick, AD and Ramanan, AV (2019) Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial. American journal of ophthalmology, 207. pp. 170-174.

Text SYCAMORE follow-up manuscript AJO - changes.doc - Author Accepted Manuscript Download (74kB)

Abstract

PURPOSE:To determine longer-term outcomes of participants enrolled from a single center in the SYCAMORE trial, a randomized placebo-controlled trial of adalimumab versus placebo in children with juvenile idiopathic arthritis-associated uveitis (JIA-U) uncontrolled on methotrexate. DESIGN:Retrospective interventional case series. METHODS:Medical records of all 28 SYCAMORE participants recruited at the Bristol Eye Hospital were reviewed at approximately 3-monthly intervals up to 5 years from the trial randomization date. Uveitis activity, treatment course, visual outcomes, ocular complications and adverse events were recorded. Data are presented using summary statistics. RESULTS:Following withdrawal of the investigational medicinal product (IMP), 25 of the 28 participants were started on adalimumab for active juvenile idiopathic arthritis-associated uveitis (JIA-U). Of the 12 participants in the active treatment arm of the SYCAMORE study, 11 (92%) were restarted on adalimumab after withdrawal of the IMP for active JIA-U (median time to flare 188 days (range 42-413)). Two participants stopped adalimumab for uncontrolled JIA-U. One participant had a reduction in vision to 0.3 due to cataract. Mean visual acuity for the remaining 27 participants was -0.04 (right eye) and -0.05 (left eye). CONCLUSIONS:Drug-induced remission of JIA-U did not persist when adalimumab was withdrawn after 1-2 years treatment. Adalimumab was well tolerated and visual acuity outcomes were excellent.

Item Type:	Article
Uncontrolled Keywords:	Humans, Uveitis, Methotrexate, Antirheumatic Agents, Treatment Outcome, Drug Therapy, Combination, Retrospective Studies, Follow-Up Studies, Visual Acuity, Dose-Response Relationship, Drug, Time Factors, Child, Female, Male, Arthritis, Juvenile, Adalimumab
Depositing User:	Symplectic Admin
Date Deposited:	04 Sep 2019 15:10
Last Modified:	19 Jan 2023 00:27
DOI:	10.1016/j.ajo.2019.06.007
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3053446